Vicenin-2: a potential radiosensitizer of non-small cell lung cancer cells

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Non-small cell lung cancer (NSCLC) exhibits resistance to conventional chemotherapy and radiotherapy.
• Vicenin-2 (VCN-2), a flavonoid from Ocimum sanctum L., possesses documented radioprotective and anti-cancer properties.
• Investigating novel agents to overcome radioresistance in NSCLC is crucial for improving patient outcomes.

Purpose of the Study:

• To evaluate the radiosensitizing potential of Vicenin-2 (VCN-2) in the NCI-H23 non-small cell lung cancer cell line.
• To assess the impact of VCN-2 on cancer cell viability, proliferation, apoptosis, and DNA damage in conjunction with radiation therapy.
• To determine the effects of VCN-2 on specific protein markers (Rad50, MMP-2, p21) and its safety profile on normal fibroblast cells.

Main Methods:

• NCI-H23 cells were treated with VCN-2 alone and in combination with X-ray irradiation.
• Assays included cytotoxicity, cell proliferation, caspase-3 activity, and DNA fragmentation.
• Western blotting was used to analyze protein expression (Rad50, MMP-2, p21), and fibroblast survival assays assessed normal cell toxicity.

Main Results:

• VCN-2, both alone and combined with radiation, significantly reduced surviving cancer cells.
• Treatment with VCN-2 increased caspase-3 activity and DNA fragmentation, indicative of enhanced apoptosis and DNA damage.
• VCN-2 modulated protein levels by increasing Rad50 and decreasing MMP-2 and p21, while exhibiting radioprotective and non-toxic effects on normal fibroblast cells.

Conclusions:

• Vicenin-2 demonstrates potent radiosensitizing properties against the NCI-H23 NSCLC cell line.
• VCN-2 exhibits direct chemotherapeutic effects on NSCLC cells.
• The findings suggest VCN-2 as a promising agent for enhancing radiotherapy efficacy in non-small cell lung cancer treatment.